比较Cullinan Oncology（纳斯达克股票代码：CGEM）和Pluristem Therapeutics（纳斯达克股票代码：PSTI）

Cullinan Oncology (NASDAQ:CGEM – Get Rating) and Pluristem Therapeutics (NASDAQ:PSTI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Earnings and Valuation

Get Cullinan Oncology alerts:

This table compares Cullinan Oncology and Pluristem Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Oncology	$18.94 million	31.71	-$65.57 million	($1.77)	-7.58
Pluristem Therapeutics	$20,000.00	1,989.40	-$49.87 million	($1.47)	-0.84

Pluristem Therapeutics has lower revenue, but higher earnings than Cullinan Oncology. Cullinan Oncology is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cullinan Oncology and Pluristem Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Oncology	0	0	2	0	3.00
Pluristem Therapeutics	0	0	0	0	N/A

Cullinan Oncology presently has a consensus price target of $52.00, suggesting a potential upside of 287.77%. Given Cullinan Oncology's higher probable upside, equities research analysts plainly believe Cullinan Oncology is more favorable than Pluristem Therapeutics.

Profitability

This table compares Cullinan Oncology and Pluristem Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cullinan Oncology	N/A	-17.75%	-17.32%
Pluristem Therapeutics	N/A	-100.63%	-55.46%

Volatility & Risk

Cullinan Oncology has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.

Insider and Institutional Ownership

93.6% of Cullinan Oncology shares are held by institutional investors. Comparatively, 16.9% of Pluristem Therapeutics shares are held by institutional investors. 21.8% of Cullinan Oncology shares are held by company insiders. Comparatively, 5.4% of Pluristem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cullinan Oncology beats Pluristem Therapeutics on 7 of the 12 factors compared between the two stocks.

About Cullinan Oncology (Get Rating)

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

About Pluristem Therapeutics (Get Rating)

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.